Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer

Clinical Cancer Research

Volumn 9, Issue 5, 2003, Pages 1666-1672

  Redman, Bruce G ^a,c,d   Esper, Peg ^a   Pan, Quintin ^a   Dunn, Rodney L ^c   Hussain, Hero K ^b   Chenevert, Thomas ^b   Brewer, George J ^b   Merajver, Sofia D ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CERULOPLASMIN; COPPER; INTERLEUKIN 6; INTERLEUKIN 8; TETRATHIOMOLYBDIC ACID; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; KIDNEY CANCER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

AGED; ANGIOGENESIS INHIBITORS; BIOLOGICAL MARKERS; CERULOPLASMIN; COPPER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOLYBDENUM; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0037652214     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Redman, B. G., Kawachi. M., and Hurwitz M. In: R. Pazdur, L. R. Coia, W. J. Hoskins, and L. D. Wagman (eds.), Cancer Management: A Multidisciplinary Approach, Ed. 6, pp. 371-386. Melville, NY: PRR, 2002.
2. Chow, W., Devesa, S. S., Warren, J. L., and Fraumeni, J. F. Rising incidence of renal cell cancer in the United States. JAMA, 281: 1628-1631, 1999.
3. Poon, R. T., Fan, S., and Wong, J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol., 19: 1207-1225, 2001.
4. Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H. Latif, F., Liu, S., Chen, F., and Duh, F. M. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet., 7: 85-90, 1994.
5. Shuin, T., Kondo, K., Torigoe, S., Kishida, T., Kubota, Y., Hosaka, M., Nagashima, Y., Kitamura, H., Latif, F., and Zbar, B. Frequent mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinoma. Cancer Res., 54: 2852-2855, 1994.
6. Gnarra, J. R., Zhou, S., Merrill, M. J., Wagner, J. R., Krumm, A., Papavassiliou, E., Oldfield, E. H., Klausner, R. D., and Linehan, W. M. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl. Acad. Sci. USA, 93: 10589-10594, 1996.
7. Dosquet, C., Coudert, M., Lepage, E., Cabane, J., and Richard, R. Are angiogenic factors, cytokines and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin. Cancer Res., 3: 2451-2458, 1997.
8. Wechsel, H. W., Bichler, K., Feil, G., Loeser, W., Lahme, S., and Petri, E. Renal cell carcinoma: relevance of angiogenic factors. Anticancer Res., 19: 1537-1540, 1999.
9. Parke, A., Bhattacherjee, P., Palmer, R. M., and Lazarus, N. R. Characterization and quantification of copper sulfate induced vascularization of the rabbit cornea. Am. J. Pathol., 137: 173-178, 1988.
10. Brem, S. S., Zagzag, D., Tsanaclis, A. M., Gately, S., Elkouby, M. P., and Brien, S. E. Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am. J. Pathol., 137: 1121-1142, 1990.
11. Yoshida, D., Ikeda, Y., and Nakazawa, S. Copper chelation inhibits tumor angiogenesis in the experimental 9L gliosarcoma model. Neurosurgery, 37: 287-292, 1995.
12. Brewer, G. J., Dick, R. D., Yuzbasiyan-Gurkin, V., Tankanow, R., Young, A. B., and Kluin, K. J. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch. Neurol., 48: 42-47, 1991.
13. Brewer, G. J., Dick, R. D., Johnson, V., Wang, Y., Yuzbasiyan-Gurkin, V., Kluin, K., Fink, J. K., and Aisen, A. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch. Neurol., 51; 545-554, 1994.
14. Brewer, G. J., Johnson, V., Dick, R. D., Kluin, K., Fink, J. K., and Brunberg, J. A. Treatment of Wilson's disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch. Neurol., 53: 1017-1025, 1996.
15. Cox, C., Teknos, T. N., Barrios, M., Brewer, G. J., Dick, R. D., and Merajver, S. D, The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope, 111: 696-701, 2002.
16. Pan, Q., Kleer, C. G., van Golen, K. L., Irani, J., Bottema, K. M., Bias, C., De Carvalho, M., Mesri, E. A., Robins, D. M., Dick, R. D., Brewer, G. J., and Merajver, S. D. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res., 62: 4854-4859, 2002.
17. Brewer, G. J., Dick, R. D., Grover, D. K., Leclaire, V., Tseng, M., Wicha, M., Pienta, K., Redman, B. G., Jahan, T., Sondak, V. K., Strawderman, M., LeCarpentier, G., and Merajver, S. D. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res., 6: 1-10, 2000.
18. Gleave, M. E., Elhilali, M., Fradet, Y., Davis, I., Venner, P., Saad, F., Klotz, L. H., Moore, M. J., Paton, V., Bajamonde, A., and the Canadian Urologic Oncology Group. Interferon γ1b compared with placebo in metastatic renal-cell carcinoma. N. Engl. J. Med., 338: 1265-1271, 1998.
19. Oliver, R. T. D., Nethersell, A. B. W., and Bottomley, J. M. Unexplained spontaneous regression and α-interferon as treatment for metastatic renal carcinoma. Br. J. Urol., 63: 128-131, 1989.
20. Dennie, J., Mandeville, J. B., and Boxerman, J. L. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn. Reson. Med., 40: 793-799, 1998.
21. Knopp, M. V., Weiss, E., Sinn, H. P., Mattern, J., Junkermann, H., Radeleff, J., Magener, A., Brix, G., Delorme, S., Zuna, I., and van Kaick, G. Pathophysiologic basis of contrast enhancement in breast tumors. J. Magn. Reson. Imaging, 10: 260-266, 1999.
22. Hawighorst, H., Libicher, M., and Knopp, M. V. Evaluation of angiogenesis and perfusion of bone marrow lesions: role of semiquantitative and quantitative dynamic MRI. J. Magn. Reson. Imaging, 10: 286-294, 1999.
23. Mayr, N., Yuh, W. T., Magnotta, V. A., Ehrhardt, J. C., Wheeler, J. A., Sorosky, J. I., Davis, C. S., Wen, B. C., Martin, D. D., Pelsang, R. E., Buller, R. E., Oberley, L. W., Mellenberg, D. E., and Hussey, D. H. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int. J. Radiat. Oncol. Biol. Phys., 36: 623-633, 1996.
24. Buadu, L. D., Murakami, J., Murayama, S., Hashiguchi, N., Sakai, S., Masuda, K., Toyoshima, S., Kuroki, S., and Ohno, S. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology, 200: 639-649, 1996.
25. Evelhoch, J. L. Key factors in the acquisition of contrast kinetic data for oncology. J. Magn. Reson. Imaging, 10: 254-259, 1999.
26. Hussain, H. K., Marrero, J. M., Nghiem, H. V., Francis, I. R., Londy, F. J., Charleston, E., and Chenevert, T. L. Dynamic contrast enhanced MRI for the assessment of change in hepatic tumor vascularity in response to anticopper antiangiogenesis therapy. Proc. Int. Soc. Magn. Reson. Med., 10: 2097, 2002.
27. Tofts, P. S. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J. Magn. Reson. Imaging, 7: 91-101, 1997.
28. Tofts, P. S., Brix, G., Buckley, D. L., Evelhoch, J. L., Henderson, E., Knopp, M. V., Larsson, H. B., Lee, T. Y., Mayr, N. A., Parker, G. J., Port, R. E., Taylor, J., and Weisskoff, R. M. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols. J. Magn. Reson. Imaging, 10: 223-232, 1999.
29. Simon, R. Optimal two-stage designs for Phase II clinical trials. Controlled Clin. Trials, 10: 1-10, 1989.
30. Walshe, J. M., and Harpet, P. L. Reversible pancytopenia secondary to treatment with tetrathiomolybdate. Br. J. Haematol., 64: 851-853, 1986.
31. Karunajeewa, H., Wall, A., Metz, J., and Grigg, A. Cytopenias secondary to copper depletion complicating ammonium tetrathiomolybdate therapy for Wilson's disease. Aust. N. Z. J. Med., 28: 215-216, 1998.
32. Motzer, R. J., Mazumder, M., Bacik, J., Berg, W., Amsterdam, A., and Ferrara, J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol., 17: 2530-2540, 1999.
33. Cristofanilli, M., Charnsangavej, C., and Hortobagyi, G. N. Angiogenesis modulation in cancer research: novel clinical approaches. Nat. Rev. Drug Discovery, 1: 415-426, 2002.